Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trialTao Jiang, Shengxiang Ren, Jianying Zhou et al.|Signal Transduction and Targeted Therapy|2021Cited by 94
A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trialYuxiang Ma, Hongyun Zhao, Yunpeng Yang et al.|Nature Medicine|2025Cited by 76